A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphon...
Huvudupphovsmän: | Reginster, J, Felsenberg, D, Cooper, C, Stakkestad, J, Miller, P, Kendler, D, Adami, S, McClung, MR, Bolognese, M, Civitelli, R, Dumont, E, Bonvoisin, B, Recker, R, Delmas, P |
---|---|
Materialtyp: | Journal article |
Språk: | English |
Publicerad: |
2006
|
Liknande verk
Liknande verk
-
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
av: Miller, P, et al.
Publicerad: (2005) -
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
av: Reginster, J, et al.
Publicerad: (2006) -
The mobile study long-term extension: Progressive improvements in efficacy with oral ibandronate (150mg) when administered monthly
av: Reginster, J, et al.
Publicerad: (2007) -
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
av: Richard Derman, et al.
Publicerad: (2009-09-01) -
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.
av: Cranney, A, et al.
Publicerad: (2009)